(Reuters) - Drugmaker Mylan NV's first-quarter revenue fell short of Wall Street forecasts as sales of emergency allergy shot EpiPen declined and the company faced intensifying competition in North America.
Mylan faces fresh worries of supply constraints for EpiPen, and on Tuesday it warned U.S. customers may have trouble getting EpiPen prescriptions filled due to problems at a manufacturing plant.
The company's revenue fell 1.3 percent to $2.68 billion in the three months ended March 31, missing analysts' average expectation of $2.75 billion, according to Thomson Reuters I/B/E/S.
North America sales of Mylan's branded products including EpiPen fell $108.7 million.
The company's net income rose 31 percent to $87.1 million or 17 cents per share in the first quarter.
Excluding one-time items, Mylan earned 96 cents per share, matching analysts' expectations.
(Reporting by Tamara Mathias in Bengaluru; Editing by Sai Sachin Ravikumar)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app